	Message from the CEO

	How We Work

	History of Schering-Plough

	Management Team

	Schering-Plough Worldwide

	Speeches & Presentations

	The Schering-Plough Foundation


	Diversity & Inclusion


	Supplier Registration

	Diversity Colleague Demographics

The Schering-Plough Foundation

The Schering-Plough Foundation, a non-profit membership corporation established in 1955, is dedicated to working with the citizens of our communities to help them realize their full potential and enhance their quality of life. The Foundation targets its grants in three major areas: health, education, community initiatives (social/civic welfare, public policy, culture and the arts and women and minorities).

Find out more about the areas in which the Foundation operates:

Health

Education

Community Initiatives

Pre-Application Questionnaire

Grant Guidelines

You will need Adobe Acrobat to download some of the documents on this page. Click here to download Adobe Acrobat.



	Brochure on the Combination

•	World Headquarters: 2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530

•	Chairman and CEO: Fred Hassan

•	Number of employees: 55,000


•	Net sales (2007): $12.7 billion


•	Business operations in more than: 140 countries

•	Largest-selling products: *VYTORIN, ZETIA, REMICADE, NASONEX.*

•	R&D investment (2007): $2.9 billion

•	Areas of research: cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health *VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.